BRPI0720551A2 - composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo

Info

Publication number
BRPI0720551A2
BRPI0720551A2 BRPI0720551-1A BRPI0720551A BRPI0720551A2 BR PI0720551 A2 BRPI0720551 A2 BR PI0720551A2 BR PI0720551 A BRPI0720551 A BR PI0720551A BR PI0720551 A2 BRPI0720551 A2 BR PI0720551A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
processes
treating cancer
Prior art date
Application number
BRPI0720551-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Foote Kevin
Theoclitou Maria-Elena
Peter Thomas Andrew
Buttar David
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0720551A2 publication Critical patent/BRPI0720551A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
BRPI0720551-1A 2006-12-21 2007-12-20 composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo BRPI0720551A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87119006P 2006-12-21 2006-12-21
US60/871190 2006-12-21
US98554207P 2007-11-05 2007-11-05
US60/985542 2007-11-05
PCT/GB2007/004917 WO2008075068A2 (en) 2006-12-21 2007-12-20 Acylaminopyrazoles as fgfr inhibitors

Publications (1)

Publication Number Publication Date
BRPI0720551A2 true BRPI0720551A2 (pt) 2019-03-12

Family

ID=39536793

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720551-1A BRPI0720551A2 (pt) 2006-12-21 2007-12-20 composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo

Country Status (28)

Country Link
US (6) US7737149B2 (enExample)
EP (1) EP2125748B1 (enExample)
JP (1) JP5000726B2 (enExample)
KR (1) KR101467593B1 (enExample)
AR (1) AR064454A1 (enExample)
AT (1) ATE510825T1 (enExample)
AU (1) AU2007336011B2 (enExample)
BR (1) BRPI0720551A2 (enExample)
CA (1) CA2672521C (enExample)
CO (1) CO6210721A2 (enExample)
CY (1) CY1111721T1 (enExample)
DK (1) DK2125748T3 (enExample)
EC (1) ECSP099436A (enExample)
HR (1) HRP20110520T1 (enExample)
IL (1) IL199019A (enExample)
MX (1) MX2009006742A (enExample)
MY (1) MY146111A (enExample)
NO (1) NO342176B1 (enExample)
NZ (1) NZ577209A (enExample)
PE (1) PE20081532A1 (enExample)
PL (1) PL2125748T3 (enExample)
PT (1) PT2125748E (enExample)
RU (1) RU2458920C2 (enExample)
SA (1) SA07280734B1 (enExample)
SI (1) SI2125748T1 (enExample)
TW (1) TWI434846B (enExample)
UY (1) UY30819A1 (enExample)
WO (1) WO2008075068A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
AR064491A1 (es) 2006-12-22 2009-04-08 Astex Therapeutics Ltd Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
WO2008078100A2 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
EP2805937A1 (en) 2007-08-22 2014-11-26 AstraZeneca AB Cyclopropyl amide derivatives
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
BRPI0914233A2 (pt) * 2008-06-19 2015-11-03 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença
JP5690741B2 (ja) 2008-12-22 2015-03-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規な多形形態の６−（１−メチル−１ｈ−ピラゾール−４−イル）−２−｛３−［５−（２−モルホリン−４−イル−エトキシ）−ピリミジン−２−イル］−ベンジル｝−２ｈ−ピリダジン−３−オンジヒドロゲンホスファートおよびその製造方法
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
JO2860B1 (en) * 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds
BR112012020782A2 (pt) * 2010-02-18 2016-05-03 Astrazeneca Ab composto, e, processo para preparar um composto
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9255072B2 (en) 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
AU2013227139B2 (en) 2012-02-28 2017-02-16 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
HK1205528A1 (en) 2012-03-08 2015-12-18 Astellas Pharma Inc. Novel fgfr3 fusion product
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体
EP3176170B1 (en) 2012-06-13 2018-11-14 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014002922A1 (ja) * 2012-06-26 2014-01-03 アステラス製薬株式会社 抗癌剤の併用による癌治療方法
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US20140179712A1 (en) * 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
WO2014151734A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
AR096393A1 (es) * 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
EP3056215B1 (en) 2013-10-08 2019-11-20 Daiichi Sankyo Company, Limited Combination of anti-fgfr2 antibody and other agent
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
PE20170774A1 (es) * 2014-08-19 2017-07-04 Shanghai Haihe Pharmaceutical Co Ltd Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3925979A3 (en) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2887148T3 (es) 2015-03-25 2021-12-21 Nat Cancer Ct Agente terapéutico contra el cáncer de vías biliares
WO2017013031A1 (en) 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
EP3339305B1 (en) 2015-08-20 2022-05-04 Zhejiang Hisun Pharmaceutical Co., Ltd Indole derivative, preparation method thereof, and use thereof in pharmaceutical drug
CN115177619A (zh) 2015-12-17 2022-10-14 卫材R&D管理有限公司 用于乳腺癌的治疗剂
CN107459519A (zh) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
US20190290641A1 (en) 2016-07-15 2019-09-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3777860A4 (en) 2018-03-28 2021-12-15 Eisai R&D Management Co., Ltd. THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA
CR20240498A (es) 2018-05-04 2025-01-08 Incyte Corp FORMAS SÓLIDAS DE UN INHIBIDOR DE FGFR Y PROCESOS PARA PREPARARLAS (Divisional EXP. 2020-0590)
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020243459A1 (en) * 2019-05-31 2020-12-03 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202237595A (zh) * 2020-12-02 2022-10-01 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之經取代噻二唑基衍生物
CN117083271A (zh) * 2020-12-02 2023-11-17 伊迪亚生物科学有限公司 作为DNA聚合酶θ抑制剂的取代的噻二唑基衍生物
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CN115819239B (zh) * 2021-09-17 2025-11-18 无锡和誉生物医药科技有限公司 一种成纤维细胞生长因子受体抑制剂的中间体及其制备方法和用途
US11957677B2 (en) 2021-10-15 2024-04-16 Cardiff Oncology, Inc. Cancer treatment using FGFR inhibitors and PLK1 inhibitors
WO2023060573A1 (en) * 2021-10-15 2023-04-20 Beijing Danatlas Pharmaceutical Co., Ltd. Novel thiadiazolyl derivatives of dna polymerase theta inhibitors
CN119301111A (zh) 2022-03-24 2025-01-10 葛兰素史密斯克莱知识产权发展有限公司 作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
WO2024031226A1 (zh) * 2022-08-08 2024-02-15 无锡和誉生物医药科技有限公司 Fgfr抑制剂的药物组合物、多晶型物及其在药学上的应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB843940A (en) 1955-09-27 1960-08-10 Kodak Ltd Method of processing photographic silver halide emulsions containing colour couplers
BE667399A (enExample) 1964-07-30 1965-11-16
JPS57150846A (en) * 1981-03-13 1982-09-17 Konishiroku Photo Ind Co Ltd Photographic element
JPS63133152A (ja) 1986-11-26 1988-06-04 Konica Corp 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料
JPH0467645A (ja) 1990-07-09 1992-03-03 Nec Kyushu Ltd バーンイン装置
JP2890065B2 (ja) 1990-11-10 1999-05-10 コニカ株式会社 ハロゲン化銀写真感光材料
JPH04184437A (ja) 1990-11-20 1992-07-01 Fuji Photo Film Co Ltd カラー画像形成方法及びハロゲン化銀カラー写真感光材料
JPH04292322A (ja) 1991-03-19 1992-10-16 Fujitsu Ltd ラック給排装置
JPH0511414A (ja) * 1991-07-02 1993-01-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
PL170837B1 (pl) * 1991-10-18 1997-01-31 Monsanto Co S rod ek g r zybobó j c zy PL PL PL PL PL PL
JPH07500116A (ja) 1992-03-26 1995-01-05 ダウエランコ 殺菌剤としてのｎ−複素環式ニトロアニリン
HRP921338B1 (en) * 1992-10-02 2002-04-30 Monsanto Co Fungicides for the control of take-all disease of plants
TW240217B (enExample) 1992-12-30 1995-02-11 Glaxo Group Ltd
JP3156026B2 (ja) 1993-12-27 2001-04-16 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
ATE262902T1 (de) 1994-11-10 2004-04-15 Millennium Pharm Inc Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
HUP0000735A3 (en) 1996-12-23 2002-03-28 Bristol Myers Squibb Pharma Co Nitrogen containing heteroaromatics as factor xa inhibitors
EP1012150A4 (en) 1997-05-19 2002-05-29 Sugen Inc HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6271237B1 (en) * 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
DK1056725T3 (da) * 1997-12-22 2006-10-02 Bayer Pharmaceuticals Corp Inhibering af raf-kinase ved hjælp af aryl- og heteroaryl-substituerede heterocykliske urinstoffer
JP3310226B2 (ja) 1998-10-16 2002-08-05 松下電器産業株式会社 音声合成方法および装置
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE60017115T2 (de) * 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. Amid-derivate und deren medizinische verwendung
AU3357700A (en) 1999-02-16 2000-09-04 E.I. Du Pont De Nemours And Company Phenoxypyrimidine insecticides and acaricides
PL353455A1 (en) 1999-08-12 2003-11-17 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
AU6909600A (en) 1999-08-13 2001-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2001021180A1 (en) * 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
HUP0302669A3 (en) * 2000-08-31 2004-03-29 Pfizer Prod Inc Pyrazole derivatives and pharmaceutical compositions containing them for treating diseases comprising abnormal cell growth and neurodegenerative diseases
US20050209297A1 (en) * 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
KR20030030029A (ko) * 2000-09-22 2003-04-16 니혼노야쿠가부시키가이샤 Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
CN100370975C (zh) * 2000-12-18 2008-02-27 株式会社医药分子设计研究所 炎症性细胞因子产生游离抑制剂
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002088090A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
JPWO2003103648A1 (ja) 2002-06-05 2005-10-06 株式会社医薬分子設計研究所 糖尿病治療薬
JPWO2003103658A1 (ja) * 2002-06-05 2005-10-06 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
EA009701B1 (ru) 2002-06-06 2008-02-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Противоаллергические средства
ES2246603B1 (es) 2002-07-03 2007-06-16 Consejo Sup. De Investig. Cientificas Procedimiento para la preparacion de esteres de hidroxitirosol, esteres obtenidos y utilizacion.
WO2004007472A1 (ja) * 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
EP1542999A1 (en) * 2002-08-01 2005-06-22 Pharmacia & Upjohn Company LLC 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
JP4171881B2 (ja) 2002-08-09 2008-10-29 株式会社大塚製薬工場 Ａｃａｔ−１阻害剤
ATE479667T1 (de) 2003-02-06 2010-09-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
JP2004292322A (ja) 2003-03-25 2004-10-21 Fuji Photo Film Co Ltd 水溶性アミド連結体の製造方法
ES2370463T3 (es) 2003-05-01 2011-12-16 Bristol-Myers Squibb Company Compuestos de pirazol - amida sustituidos con arilo útiles como inhibidores de quinasa.
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US7115359B2 (en) * 2003-07-25 2006-10-03 Konica Minolta Medical & Graphic, Inc. Photothermographic material
CA2536151A1 (en) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
US7432271B2 (en) * 2003-09-02 2008-10-07 Bristol-Myers Squibb Company Pyrazolyl inhibitors of 15-lipoxygenase
US20050171171A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as FLT-3 modulators
DK1689721T3 (da) 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
US7652146B2 (en) * 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
DE602005020611D1 (de) 2004-04-28 2010-05-27 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CA2615890A1 (en) 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof

Also Published As

Publication number Publication date
US8129391B2 (en) 2012-03-06
US7737149B2 (en) 2010-06-15
US20170260143A1 (en) 2017-09-14
WO2008075068A3 (en) 2008-10-02
CO6210721A2 (es) 2010-10-20
ECSP099436A (es) 2009-07-31
RU2458920C2 (ru) 2012-08-20
WO2008075068A2 (en) 2008-06-26
AR064454A1 (es) 2009-04-01
HK1139137A1 (en) 2010-09-10
AU2007336011B2 (en) 2011-09-22
JP2010513444A (ja) 2010-04-30
US8604022B2 (en) 2013-12-10
SI2125748T1 (sl) 2011-08-31
NO20092033L (no) 2009-08-06
CA2672521A1 (en) 2008-06-26
DK2125748T3 (da) 2011-08-01
PE20081532A1 (es) 2008-12-12
TWI434846B (zh) 2014-04-21
US20080153812A1 (en) 2008-06-26
US20120129844A1 (en) 2012-05-24
IL199019A0 (en) 2010-02-17
MX2009006742A (es) 2009-08-24
CA2672521C (en) 2015-03-17
EP2125748A2 (en) 2009-12-02
EP2125748B1 (en) 2011-05-25
US9688640B2 (en) 2017-06-27
JP5000726B2 (ja) 2012-08-15
CY1111721T1 (el) 2015-10-07
IL199019A (en) 2014-06-30
SA07280734B1 (ar) 2010-09-29
PT2125748E (pt) 2011-07-20
US20100273811A1 (en) 2010-10-28
HRP20110520T1 (hr) 2011-08-31
RU2009127644A (ru) 2011-01-27
US10301267B2 (en) 2019-05-28
KR20090094026A (ko) 2009-09-02
UY30819A1 (es) 2008-07-31
US20150299134A1 (en) 2015-10-22
NZ577209A (en) 2012-04-27
KR101467593B1 (ko) 2014-12-01
MY146111A (en) 2012-06-29
AU2007336011A1 (en) 2008-06-26
NO342176B1 (no) 2018-04-09
TW200831500A (en) 2008-08-01
US20140066455A1 (en) 2014-03-06
PL2125748T3 (pl) 2011-09-30
ATE510825T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI1006115A8 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
AR063628A1 (es) Compuestos de piridinona utiles para el tratamiento de cancer
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
BRPI0915084B8 (pt) composto, e, composição farmacêutica
CL2007003352A1 (es) Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007003627A1 (es) Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias
TW200621762A (en) Novel compounds
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
UY30282A1 (es) Compuestos quimicos
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
TNSN07419A1 (en) Methods for treating drug resistant cancer
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
WO2013040227A3 (en) Therapeutic compounds
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]